



Express Mail No.: EV 452 775 855 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Fleischer and Reimer

Confirmation No.: 9935

Serial No.: 09/701,450

Group Art Unit: 1615

Filed: November 27, 2000

Examiner: Gollamudi S. Kishore

For: PREPARATIONS FOR THE APPLICATION OF  
ANTI-INFLAMMATORY, ESPECIALLY  
ANTISEPTIC AGENTS AND/OR AGENTS  
PROMOTING THE HEALING OF WOUNDS TO  
THE LOWER RESPIRATORY TRACT

Attorney Docket No.: 11390-005-999

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of Applicants or Applicants' attorneys which are or may be related to patentability of the claimed invention, Applicants hereby direct the Examiner's attention to references A01- A03, B01 - B15 and C01 - C22, which are listed on the accompanying List of References Cited by Applicant. Copies of References A01- A03, B01 - B15 and C01 - C22 are submitted herewith.

Identification of the listed references are not to be construed an admission by Applicants or Applicants' attorneys that such references are available as "prior art" against the subject application.

Pursuant to 37 C.F.R. § 1.97(b)(a), no fee is believed to be due. However, if required, please charge any required fee to Jones Day Deposit Account No. 50-3013. A copy of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: June 22, 2005

Samuel B. Abrams 30,605  
Samuel B. Abrams (Reg. No.)

By: William J. Thomann 40,203  
William J. Thomann (Reg. No.)  
JONES DAY  
222 East 41<sup>st</sup> Street  
New York, New York 10017-6702  
(212) 901-9028


Express Mail No.: **EV 452 775 855 US**
**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

ATTY DOCKET NO.

11390-005-999

APPLICATION NO

09/701,450

APPLICANT

Fleischer and Reimer

FILING DATE

November 27, 2000

GROUP

1615

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	4,704,838	11/03/1987	McNamara et al.			
	A02	5,006,343	04/9/1991	Benson et al.			
	A03	5,942,245	08/24/1999	Katinger et al.			

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01	CA 1 323 568	10/26/1993	Canada				
	B02	CA 2 204 493 A1	05/17/1996	Canada				
	B03	CA 2 332 389 A1	05/27/1999	Canada				
	B04	CA 2 215 716	07/12/1999	Canada				
	B05	EP 0 267 050 A2	5/11/1988	EPO				
	B06	EP 1 013 269	06/28/200	EPO				
	B07	WO 87/07502	12/17/1987	PCT				
	B08	WO 88/01862	03/24/1998	PCT				
	B09	WO 91/16882	11/14/1991	PCT				
	B10	WO 92/13873	08/20/1992	PCT				
	B11	WO 96/19199	06/27/1996	PCT				
	B12	WO 96/22764	08/01/1996	PCT				
	B13	WO 96/35435	11/14/1996	PCT				
	B14	WO 98/05340	02/12/1998	PCT				
	B15	JP 02-204413	08/14/1990	Japan (include English abstract)			X	

**OTHER REFERENCES** (Including Author, Title, Date, Pertinent Pages, Etc.)

	C01	Aeorols in Medicine, 1993, pp. 72-83 and 118-156
	C02	Osaka Pref. Hospital Pharmacist Association, "Drug Directory", 1995, Povidone Iodine, translation of pertinent part
	C03	Bonowitz et al., 2001, "Comparative therapeutic and toxic effects of different povidone iodine (PVP-I) formations in a model of oral candidosis based on in vitro reconstituted epithelium," J. Drug Targeting 9:75-83

	C04	Brogmann et al., 1998, "Liposomal PVP-Iodine Eye Drops - A New Drug Delivery System For an Approved Active Ingredient", Arch Pharm Med Chem 331 (Suppl. 2): 52.
	C05	Damour et al, 1992, "Cytotoxicity evaluation of antiseptics and antibiotics on cultured human fibroblasts and keratinocytes", Berns 18 (6): 479-485.
	C06	Ganzer et al., 2001, "Efficacy and tolerability of povidone-iodine liposome complex in infected knee joints of rabbits" 11 <sup>th</sup> Eur Con Clin Microbiol Inf Ds, Istanbul, Turkey April 2001, Clin Microbiol Inf 2001; 7 Suppl 1:262, Poster and Abstract.
	C07	Hauser et al., 2001, "Liposomal PVP-iodine hydrogel improves epithelialization of meshed skin grafts - evaluation of the combined effects of moisture and antiseptics," The Plastic Surgery Research Council 46th Annual Meeting June 9-12, Milwaukee, WI 36.346
	C08	Kallengerger et al., 1991, Hyg + Med 16:383-395
	C09	Kiss et al., 1994, "Toxic Effects of Heavy Metals on Ionic Channels", Pharma Reviews 46 (3): 245-267.
	C10	Lineaweaver et al., 1985, Arch Surg 120:257-270
	C11	Mayer et al., 1993, "Povidone-Iodine and Wound Healing: A Critical Review", Wounds 5(1): 14-23
	C12	Reimer et al., 1997, "Povidone-Iodine Liposomes - An Overview," Dermatology 195(Suppl. 2):93-99
	C13	Reimer, et al., 2000, "In vitro and in vivo investigations of an innovative topical drug formulation for infection treatment and wound healing: Povidone iodine liposome hydrogen" Dermatology 201:235-241, Abstract.
	C14	Reimer et al., 1999, "Povidone-iodine liposome complex - a novel anti-infective for topical treatment," Clin. Microbial Inf. 5(Suppl. 3):136, 9th European Conference of Clin. Microbiol. and Infect. Dis., Berlin, March 99, Abstract
	C15	Reimer et al, 2000, "Povidone-Iodine Liposome Complex", 10 <sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases, May 2000, Abstract.
	C16	Reimer et al, 1998, "Povidone-Iodine Liposomes - Development of a Novel Anti-Infective for Topical Treatment", 4 <sup>th</sup> International conference of the Hospital Infection Society, J. Hosp. Infect 40 (Suppl. A), Abstract and Poster
	C17	Stratord et al., 1983, "Effects of topically applied liposomes on disposition of epinephrine and inulin in the albino rabbit eye" Int'l J. of Pharma 13:263-272
	C18	Weiner et al., 1989, Drug Development and Industrial Pharmacy, 15(10):1523-1554
	C19	Wutzler et al., 1999, "Virucidal and chlamydical activities of eye drops with povidone-iodine liposome complex," Ophthalmic Res. 32:118-125
	C20	Wutzler et al., 2001, "Virucidal activity and cytotoxicity of the liposomal formulation of povidone-iodine", 14 <sup>th</sup> International Conference on Antiviral Research, April 2001. Abstract and Poster
	C21	Wutzler et al., 2002, "Virucidal activity and cytotoxicity of the liposomal formulation of povidone-iodine," Ophthalmic Res. 54: 89-87
	C22	Xiaonan Cia, 1994, "The Clinical Use and Dosage Form of Iodophors", Bulletin of the Medical School of Shantou University (2):77

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: EV 452 775 855 US

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)				ATTY DOCKET NO.		APPLICATION NO	
				11390-005-999		09/701,450	
				APPLICANT			
				Fleischer and Reimer			
				FILING DATE		GROUP	
				November 27, 2000		1615	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	4,704,838	11/03/1987	McNamara et al.			
	A02	5,006,343	04/9/1991	Benson et al.			
	A03	5,942,245	08/24/1999	Katinger et al.			

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01	CA 1 323 568	10/26/1993	Canada				
	B02	CA 2 204 493 A1	05/17/1996	Canada				
	B03	CA 2 332 389 A1	05/27/1999	Canada				
	B04	CA 2 215 716	07/12/1999	Canada				
	B05	EP 0 267 050 A2	5/11/1988	EPO				
	B06	EP 1 013 269	06/28/200	EPO				
	B07	WO 87/07502	12/17/1987	PCT				
	B08	WO 88/01862	03/24/1998	PCT				
	B09	WO 91/16882	11/14/1991	PCT				
	B10	WO 92/13873	08/20/1992	PCT				
	B11	WO 96/19199	06/27/1996	PCT				
	B12	WO 96/22764	08/01/1996	PCT				
	B13	WO 96/35435	11/14/1996	PCT				
	B14	WO 98/05340	02/12/1998	PCT				
	B15	JP 02-204413	08/14/1990	Japan (include English abstract)			X	

**OTHER REFERENCES** *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	C01	Aeorols in Medicine, 1993, pp. 72-83 and 118-156
	C02	Osaka Pref. Hospital Pharmacist Association, "Drug Directory", 1995, Povidone Iodine, translation of pertinent part
	C03	Bonowitz et al., 2001, "Comparative therapeutic and toxic effects of different povidone iodine (PVP-I) formations in a model of oral candidosis based on in vitro reconstituted epithelium," J. Drug Targeting 9:75-83

C04	Brogmann et al., 1998, "Liposomal PVP-Iodine Eye Drops - A New Drug Delivery System For an Approved Active Ingredient", Arch Pharm Med Chem 331 (Suppl. 2): 52.
C05	Damour et al, 1992, "Cytotoxicity evaluation of antiseptics and antibiotics on cultured human fibroblasts and keratinocytes", Berns 18 (6): 479-485.
C06	Ganzer et al., 2001, "Efficacy and tolerability of povidone-iodine liposome complex in infected knee joints of rabbits" 11 <sup>th</sup> Eur Con Clin Microbiol Inf Ds, Istanbul, Turkey April 2001, Clin Microbiol Inf 2001; 7 Suppl 1:262, Poster and Abstract.
C07	Hauser et al., 2001, "Liposomal PVP-iodine hydrogel improves epithelialization of meshed skin grafts - evaluation of the combined effects of moisture and antisepsis," The Plastic Surgery Research Council 46th Annual Meeting June 9-12, Milwaukee, WI 36.346
C08	Kallengerger et al., 1991, Hyg + Med 16:383-395
C09	Kiss et al., 1994, "Toxic Effects of Heavy Metals on Ionic Channels", Pharma Reviews 46 (3): 245-267.
C10	Lineaweaver et al., 1985, Arch Surg 120:257-270
C11	Mayer et al., 1993, "Povidone-Iodine and Wound Healing: A Critical Review", Wounds 5(1): 14-23
C12	Reimer et al., 1997, "Povidone-Iodine Liposomes - An Overview," Dermatology 195(Suppl. 2):93-99
C13	Reimer, et al., 2000, "In vitro and in vivo investigations of an innovative topical drug formulation for infection treatment and wound healing: Povidone iodine liposome hydrogen" Dermatology 201:235-241, Abstract.
C14	Reimer et al., 1999, "Povidone-iodine liposome complex - a novel anti-infective for topical treatment," Clin. Microbial Inf. 5(Suppl. 3):136, 9th European Conference of Clin. Microbiol. and Infect. Dis., Berlin, March 99, Abstract
C15	Reimer et al, 2000, "Povidone-Iodine Liposome Complex", 10 <sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases, May 2000, Abstract.
C16	Reimer et al, 1998, "Povidone-Iodine Liposomes - Development of a Novel Anti-Infective for Topical Treatment", 4 <sup>th</sup> International conference of the Hospital Infection Society, J. Hosp. Infect 40 (Suppl. A), Abstract and Poster
C17	Stratford et al., 1983, "Effects of topically applied liposomes on disposition of epinephrine and inulin in the albino rabbit eye" Int'l J. of Pharma 13:263-272
C18	Weiner et al., 1989, Drug Development and Industrial Pharmacy, 15(10):1523-1554
C19	Wutzler et al., 1999, "Virucidal and chlamydical activities of eye drops with povidone-iodine liposome complex," Ophthalmic Res. 32:118-125
C20	Wutzler et al., 2001, "Virucidal activity and cytotoxicity of the liposomal formulation of povidone-iodine", 14 <sup>th</sup> International Conference on Antiviral Research, April 2001. Abstract and Poster
C21	Wutzler et al., 2002, "Virucidal activity and cytotoxicity of the liposomal formulation of povidone-iodine," Ophthalmic Res. 54: 89-87
C22	Xiaonan Cia, 1994, "The Clinical Use and Dosage Form of Iodophors", Bulletin of the Medical School of Shantou University (2):77

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.